spherical-nucleic-acids
(2)
Flashpoint Therapeutics
Flashpoint Therapeutics is a clinical-stage biotech spun out of Chad Mirkin's nanotechnology lab at Northwestern University, developing 'structural nanomedicines' - drugs whose potency comes not from new molecules but from how existing therapeutic components are arranged at the nanoscale. By co-delivering RNA, DNA, peptide and CRISPR payloads to individual cells with precise stoichiometry and synchronized activation, the company reports it can turn conventionally ineffective drug components into curative therapies, with early data showing dramatically stronger immune activation and tumor killing. Founded by Adam Margolin and backed by a $10M seed round led by Riyadh-based Beta Lab plus a $50M KAIMRC partnership, Flashpoint is advancing its lead immuno-oncology candidate FLASH-001 through the clinic.
Adam Margolin
Adam Margolin is a computational biologist turned biotech founder who co-founded Flashpoint Therapeutics, a clinical-stage company engineering spherical-nucleic-acid nanomedicines that aim to turn weak cancer therapies into curative ones. After a 20-year academic career that took him from Wharton and Wall Street to running the #3-ranked genetics department in the country at Mount Sinai, and a stint as a Venture Partner at Khosla Ventures, he teamed with Northwestern nanotech pioneer Chad Mirkin to build Flashpoint. He led the company as founding CEO through a $10M seed round before handing the chief executive role to biotech veteran Barry Labinger in 2025. His mission is deeply personal: his mother died of cancer when he was three.